Top

BMC Public Health

Published in:

Open Access 01-12-2024 | Colorectal Cancer | Research

Association of the triglyceride-glucose index with the occurrence and recurrence of colorectal adenomas: a retrospective study from China

Authors: Jiaoyan Li, Jingfeng Chen, Haoshuang Liu, Su Yan, Youxiang Wang, Miao Xing, Suying Ding

Published in: BMC Public Health | Issue 1/2024

Abstract

Background

Resection of colorectal adenoma (CRA) prevents colorectal cancer; however, recurrence is common. We aimed to assess the association of the triglyceride-glucose (TyG) index with CRA occurrence and recurrence.

Methods

Data from 3392 participants at a hospital in China from 2020 to 2022 were analyzed. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). A restricted cubic spline was used to fit TyG index dose‒response curves to recurrent adenomas. The discriminatory power of TyG index for predicting later recurrence was assessed with the area under the receiver operating characteristic (ROC) curve in 170 patients with a TyG index at initial adenoma diagnosis.

Results

One thousand five hundred ninety-six adenoma and 1465 normal participants were included in the occurrence analysis, and 179 recurrent and 152 nonrecurrent participants were included in the recurrence analysis. The TyG mutation was an independent risk factor for CRA occurrence and recurrence. After adjusting for confounders, the risk of adenoma in the participants in Q2, Q3, and Q4 groups of TyG was 1.324 (95% CI 1.020–1.718), 1.349 (95% CI 1.030–1.765), and 1.445 (95% CI 1.055–1.980) times higher than that of the Q1, respectively, and the risk of recurrence in the Q3 and Q4 groups was 2.267 (95% CI 1.096–4.691) and 2.824 (95% CI 1.199–6.648) times in Q1 group. Multiple logistic regression showed that the highest quartile of the TyG index was associated with a greater risk of advanced adenoma recurrence (OR 4.456, 95% CI 1.157–17.164), two or more adenomas (OR 5.079, 95% CI 1.136–22.714 [after removal of TyG index extreme values]), and proximal colon or both adenomas (OR 3.043, 95% CI 1.186–7.810). Subgroup analysis revealed that the association was found to be present only in participants of all age groups who were either male or without obesity, hyperglycemia, hypertension, or dyslipidemia (p < 0.05). ROC curves illustrated that the TyG index had good predictive efficacy for identifying recurrence, especially for patients with two or more adenomas (AUC 0.777, 95% CI 0.648–0.907).

Conclusions

An increase in the TyG index is associated with an increased risk of adenoma occurrence and recurrence, with a stronger association with the latter.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Cotton S, Sharp L, Little J. The adenoma-carcinoma sequence and prospects for the prevention of colorectal neoplasia. Crit Rev Oncog. 1996;7(5–6):293–342. https://doi.org/10.1615/critrevoncog.v7.i5-6.10.CrossRefPubMed

Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977–81. https://doi.org/10.1056/NEJM199312303292701.CrossRefPubMed

Doubeni CA, Corley DA, Quinn VP, Jensen CD, Zauber AG, Goodman M, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut. 2018;67(2):291–8. https://doi.org/10.1136/gutjnl-2016-312712.CrossRefPubMed

Atkin W, Wooldrage K, Brenner A, Martin J, Shah U, Perera S, et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol. 2017;18(6):823–34. https://doi.org/10.1016/S1470-2045(17)30187-0.CrossRefPubMedPubMedCentral

Cottet V, Jooste V, Fournel I, Bouvier AM, Faivre J, Bonithon-Kopp C. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut. 2012;61(8):1180–6. https://doi.org/10.1136/gutjnl-2011-300295.CrossRefPubMed

Neugut AI, Jacobson JS, Ahsan H, Santos J, Garbowski GC, Forde KA, et al. Incidence and recurrence rates of colorectal adenomas: a prospective study. Gastroenterology. 1995;108:402–8. https://doi.org/10.1016/0016-5085(95)90066-7.CrossRefPubMed

Martínez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology. 2009;136(3):832–41. https://doi.org/10.1053/j.gastro.2008.12.007.CrossRefPubMed

Wang X, Häring MF, Rathjen T, Lockhart SM, Sørensen D, Ussar S, et al. Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene. 2017;36(35):4987–96. https://doi.org/10.1038/onc.2017.107.CrossRefPubMedPubMedCentral

10.

Chen X, Liang H, Song Q, Xu X, Cao D. Insulin promotes progression of colon cancer by upregulation of ACAT1. Lipids Health Dis. 2018;17(1):122. https://doi.org/10.1186/s12944-018-0773-x.CrossRefPubMedPubMedCentral

11.

Kasprzak A. Insulin-Like Growth Factor 1 (IGF-1) signaling in glucose metabolism in colorectal cancer. Int J Mol Sci. 2021;22(12):6434. https://doi.org/10.3390/ijms22126434.CrossRefPubMedPubMedCentral

12.

Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86(3):s836–42. https://doi.org/10.1093/ajcn/86.3.836S.CrossRefPubMed

13.

Farahani H, Mahmoudi T, Asadi A, Nobakht H, Dabiri R, Hamta A. Insulin resistance and colorectal cancer risk: the role of elevated plasma resistin levels. J Gastrointest Cancer. 2020;51(2):478–83. https://doi.org/10.1007/s12029-019-00260-7.CrossRefPubMed

14.

Kasprzak A. Autophagy and the Insulin-like Growth Factor (IGF) system in colonic cells: implications for colorectal neoplasia. Int J Mol Sci. 2023;24(4):3665. https://doi.org/10.3390/ijms24043665.CrossRefPubMedPubMedCentral

15.

Yoon YS, Keum N, Zhang X, Cho E, Giovannucci EL. Hyperinsulinemia, insulin resistance and colorectal adenomas: a meta-analysis. Metabolism. 2015;64(10):1324–33. https://doi.org/10.1016/j.metabol.2015.06.013.CrossRefPubMed

16.

Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304. https://doi.org/10.1089/met.2008.0034.CrossRefPubMed

17.

Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínezabundis E, Ramoszavala MG, Hernándezgonzález SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–51. https://doi.org/10.1210/jc.2010-0288.CrossRefPubMed

18.

Vasques AC, Novaes FS, de Oliveira MS, Souza JR, Yamanaka A, Pareja JC, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93(3):e98–100. https://doi.org/10.1016/j.diabres.2011.05.030.CrossRefPubMed

19.

Ramdas Nayak VK, Satheesh P, Shenoy MT, Kalra S. Triglyceride Glucose (TyG) Index: A surrogate biomarker of insulin resistance. J Pak Med Assoc. 2022;72(5):986–8. https://doi.org/10.47391/JPMA.22-63.CrossRefPubMed

20.

Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214–23. https://doi.org/10.1152/ajpendo.1979.237.3.E214.CrossRefPubMed

21.

Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study. BMC Endocr Disord. 2020;20(1):113. https://doi.org/10.1186/s12902-020-00581-w.CrossRefPubMedPubMedCentral

22.

Li W, Liu T, Qian L, Wang Y, Ma X, Cao L, et al. Insulin resistance and inflammation mediate the association of abdominal obesity with colorectal cancer risk. Front Endocrinol (Lausanne). 2022;13:983160. https://doi.org/10.3389/fendo.2022.983160.CrossRefPubMed

23.

Liu T, Zhang Q, Wang Y, Ma X, Zhang Q, Song M, et al. Association between the TyG index and TG/HDL-C ratio as insulin resistance markers and the risk of colorectal cancer. BMC Cancer. 2022;22(1):1007. https://doi.org/10.1186/s12885-022-10100-w.CrossRefPubMedPubMedCentral

24.

Fritz J, Bjørge T, Nagel G, Manjer J, Engeland A, Häggström C, et al. The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. Int J Epidemiol. 2020;49(1):193–204. https://doi.org/10.1093/ije/dyz053.CrossRefPubMed

25.

Han M, Wang H, Yang S, Zhu S, Zhao G, Shi H, et al. Triglyceride glucose index and Atherogenic index of plasma for predicting colorectal neoplasms in patients without cardiovascular diseases. Front Oncol. 2022;12:1031259. https://doi.org/10.3389/fonc.2022.1031259.CrossRefPubMedPubMedCentral

26.

Flood A, Mai V, Pfeiffer R, Kahle L, Rosen CJ, Lanza E, et al. Serum concentrations of insulin-like growth factor and insulin-like growth factor binding protein 3 and recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1493–8. https://doi.org/10.1158/1055-9965.EPI-08-0048.CrossRefPubMedPubMedCentral

27.

Flood A, Mai V, Pfeiffer R, Kahle L, Remaley AT, Lanza E, et al. Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. Gastroenterology. 2007;133(5):1423–9. https://doi.org/10.1053/j.gastro.2007.08.040.CrossRefPubMed

28.

Kang M, Peery AF, Locklear C, Galanko JA, Sandler RS, Keku TO. Plasma insulin, glucose, IGF-I, IGF-II, and IGFBP-3 and risk of recurrent colorectal adenomas. J Gastroenterol Hepatol Res. 2013;2(4):531–5. https://doi.org/10.6051/j.issn.2224-3992.2013.02.247.CrossRefPubMedPubMedCentral

29.

Chen C, Lu FC, Department of Disease Control Ministry of Health PC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004;17(Suppl):1–36.PubMed

30.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. https://doi.org/10.1001/jama.289.19.2560.CrossRefPubMed

31.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7%3c539::AID-DIA668%3e3.0.CO;2-S.CrossRefPubMed

32.

Revision JCFG. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1–29. https://doi.org/10.11909/j.issn.1671-5411.2018.01.011.CrossRef

33.

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8. https://doi.org/10.1111/his.13975.CrossRefPubMed

34.

Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the us multi-society task force on colorectal cancer. Am J Gastroenterol. 2020;115(3):415–34. https://doi.org/10.14309/ajg.0000000000000544.CrossRefPubMedPubMedCentral

35.

Stevanato Filho PR, Aguiar Júnior S, Begnami MD, Kuasne H, Spencer RM, Nakagawa WT, et al. Oestrogen receptor beta isoform expression in sporadic colorectal cancer, familial adenomatous polyposis and progressive stages of colorectal cancer. BMC Cancer. 2017;17(1):754. https://doi.org/10.1186/s12885-017-3688-4.CrossRefPubMedPubMedCentral

36.

Hang D, He X, Kværner AS, Chan AT, Wu K, Ogino S, et al. Plasma sex hormones and risk of conventional and serrated precursors of colorectal cancer in postmenopausal women. BMC Med. 2021;19(1):18. https://doi.org/10.1186/s12916-020-01895-1.CrossRefPubMedPubMedCentral

37.

Jacobs ET, Martínez ME, Alberts DS, Jiang R, Lance P, Lowe KA, et al. Association between body size and colorectal adenoma recurrence. Clin Gastroenterol Hepatol. 2007;5(8):982–90. https://doi.org/10.1016/j.cgh.2007.03.022.CrossRefPubMedPubMedCentral

38.

Lin CC, Huang KW, Luo JC, Wang YW, Hou MC, Lin HC, et al. Hypertension is an important predictor of recurrent colorectal adenoma after screening colonoscopy with adenoma polypectomy. J Chin Med Assoc. 2014;77(10):508–12. https://doi.org/10.1016/j.jcma.2014.03.007.CrossRefPubMed

39.

Liu B, Wen P, Gu X, Weng R, Liu S. Elevated serum triglyceride predicts recurrence of colorectal polyps in patients with advanced adenomas. Lipids Health Dis. 2020;19(1):211. https://doi.org/10.1186/s12944-020-01388-3.CrossRefPubMedPubMedCentral

40.

Wong MCS, Leung EY, Chun SCC, Deng Y, Lam T, Tang RSY, et al. Recurrence rates of advanced colorectal neoplasia (ACN) in subjects with baseline ACN followed up at different surveillance intervals. Dig Liver Dis. 2023;55(12):1742–9. https://doi.org/10.1016/j.dld.2023.03.019.CrossRefPubMed

41.

van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101(2):343–50. https://doi.org/10.1111/j.1572-0241.2006.00390.x.CrossRefPubMed

42.

Loffeld RJ. Are many colorectal cancers due to missed adenomas? Eur J Intern Med. 2009;20(1):20–3. https://doi.org/10.1016/j.ejim.2008.03.013.CrossRefPubMed

Title: Association of the triglyceride-glucose index with the occurrence and recurrence of colorectal adenomas: a retrospective study from China
Authors: Jiaoyan Li
Jingfeng Chen
Haoshuang Liu
Su Yan
Youxiang Wang
Miao Xing
Suying Ding
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Insulins
Insulins
Dyslipidemia
Published in: BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI: https://doi.org/10.1186/s12889-024-18076-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association of the triglyceride-glucose index with the occurrence and recurrence of colorectal adenomas: a retrospective study from China

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Making sense of COVID-19: manifestations of health capital during the pandemic

Differences in children’s exposure to television advertising of unhealthy foods and beverages in Spain by socio-economic level

Recurrent Vulvovaginal Candidiasis: Assessing the relationship between feminine/vaginal washes and other factors among Ghanaian women

Evaluating the risk of conflict on recent Ebola outbreaks in Guinea and the Democratic Republic of the Congo

Diabetes mellitus and associated risk factors among HIV infected patients on HAART

A study on the influencing factors of mental health of Chinese garden workers: a cross-sectional study